HER2-positive breast and gastric cancer prognosis have dramatically improved because of HER2-targeted therapy. There are currently no HER2-targeted medicines with approved indications for treating non-small…
View More Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer